Alnylam Pharmaceuticals
Rocheās $310 Million Gamble On Alnylam Pays Off As Hypertension Drug Shows Promise In Phase 2
Anika Sharma
Roche’s recent investment of $310 million into metabolic therapy is yielding positive results, as its collaboration with Alnylam in the ...
Legal Engagements Amid Scientific Advancements: Alnylam’s Ongoing Interplay with Moderna
Anika Sharma
In the intricate choreography of the biopharmaceutical world, where innovation and intellectual property intertwine, a dramatic legal ballet unfolds. Alnylam, ...
At the AAIC, Alnylam presents a long-acting amyloid medication
SG Tylor
Source – Alnylam Pharmaceuticals Alnylam has presented promising preliminary clinical results for its new RNA interference candidate, ALN-APP, which targets ...
